Acadian Asset Management LLC lowered its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 0.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,223,517 shares of the specialty pharmaceutical company’s stock after selling 3,173 shares during the period. Acadian Asset Management LLC owned approximately 3.49% of AMAG Pharmaceuticals worth $22,510,000 as of its most recent filing with the SEC.
Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. boosted its stake in AMAG Pharmaceuticals by 67,790.9% in the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock valued at $112,647,000 after buying an additional 4,988,054 shares during the period. State Street Corp boosted its stake in AMAG Pharmaceuticals by 75.2% in the first quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock valued at $56,876,000 after buying an additional 1,082,366 shares during the period. Dimensional Fund Advisors LP boosted its stake in AMAG Pharmaceuticals by 152.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock valued at $23,129,000 after buying an additional 619,370 shares during the period. Norges Bank acquired a new stake in AMAG Pharmaceuticals during the fourth quarter valued at $19,914,000. Finally, Perceptive Advisors LLC boosted its stake in AMAG Pharmaceuticals by 2,768.3% in the first quarter. Perceptive Advisors LLC now owns 560,000 shares of the specialty pharmaceutical company’s stock valued at $12,628,000 after buying an additional 540,476 shares during the period.
Shares of AMAG Pharmaceuticals, Inc. (AMAG) traded down 5.66% during mid-day trading on Wednesday, hitting $17.50. The company had a trading volume of 811,612 shares. The company’s market capitalization is $613.29 million. AMAG Pharmaceuticals, Inc. has a 1-year low of $16.00 and a 1-year high of $36.83. The company has a 50-day moving average price of $18.97 and a 200-day moving average price of $21.04.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.18. The business had revenue of $158.39 million during the quarter, compared to the consensus estimate of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business’s revenue was up 24.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.45 EPS. On average, equities analysts anticipate that AMAG Pharmaceuticals, Inc. will post ($0.41) EPS for the current year.
WARNING: This article was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://stocknewstimes.com/2017/08/09/acadian-asset-management-llc-has-22-51-million-position-in-amag-pharmaceuticals-inc-nasdaqamag-updated.html.
Several equities research analysts have weighed in on AMAG shares. ValuEngine cut AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 target price for the company in a research note on Tuesday, July 11th. Cantor Fitzgerald restated a “hold” rating and issued a $23.00 target price on shares of AMAG Pharmaceuticals in a research note on Tuesday, May 2nd. BidaskClub upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $34.00 target price (down previously from $40.00) on shares of AMAG Pharmaceuticals in a research note on Wednesday, May 3rd. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $28.09.
In other news, SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $98,760.00. Following the completion of the sale, the senior vice president now owns 28,336 shares in the company, valued at approximately $566,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.80% of the stock is owned by company insiders.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
